Biora Therapeutics, Inc. (BIOR)
(Delayed Data from NSDQ)
$0.66 USD
-0.04 (-6.02%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $0.66 0.00 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.66 USD
-0.04 (-6.02%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $0.66 0.00 (0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Butterfly Network (BFLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Butterfly Network, Inc. (BFLY) and Biora Therapeutics, Inc. (BIOR) have performed compared to their sector so far this year.
Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Biora Therapeutics, Inc. (BIOR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biora Therapeutics, Inc. (BIOR) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?